vs
Side-by-side financial comparison of Accenture (ACN) and Merck & Co. (MRK). Click either name above to swap in a different company.
Accenture is the larger business by last-quarter revenue ($18.0B vs $16.3B, roughly 1.1× Merck & Co.). Accenture runs the higher net margin — 10.3% vs 0.9%, a 9.4% gap on every dollar of revenue. On growth, Accenture posted the faster year-over-year revenue change (8.3% vs 4.9%). Over the past eight quarters, Accenture's revenue compounded faster (4.9% CAGR vs 0.5%).
Accenture plc is a Irish technology consulting company headquartered in Dublin, Ireland. Founded in 1989, Accenture provides information technology and management consulting services across 120 countries globally.
Merck & Co., Inc. is an American multinational pharmaceutical company headquartered in Rahway, New Jersey. The company does business as Merck Sharp & Dohme or MSD outside the United States and Canada. The company is ranked fourth on the list of largest biomedical companies by revenue.
ACN vs MRK — Head-to-Head
Income Statement — Q3 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $18.0B | $16.3B |
| Net Profit | $1.9B | $141.0M |
| Gross Margin | — | 74.2% |
| Operating Margin | 13.8% | — |
| Net Margin | 10.3% | 0.9% |
| Revenue YoY | 8.3% | 4.9% |
| Net Profit YoY | 2.1% | -9.5% |
| EPS (diluted) | $2.93 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $18.0B | $16.3B | ||
| Q4 25 | $18.7B | $16.4B | ||
| Q3 25 | $17.6B | $17.3B | ||
| Q2 25 | $17.7B | $15.8B | ||
| Q1 25 | $16.7B | $15.5B | ||
| Q4 24 | $17.7B | $15.6B | ||
| Q3 24 | $16.4B | $16.7B | ||
| Q2 24 | — | $16.1B |
| Q1 26 | $1.8B | $141.0M | ||
| Q4 25 | $2.2B | $3.0B | ||
| Q3 25 | $1.4B | $5.8B | ||
| Q2 25 | $2.2B | $4.4B | ||
| Q1 25 | $1.8B | $5.1B | ||
| Q4 24 | $2.3B | $3.7B | ||
| Q3 24 | $1.7B | $3.2B | ||
| Q2 24 | — | $5.5B |
| Q1 26 | 30.3% | 74.2% | ||
| Q4 25 | 33.1% | 66.2% | ||
| Q3 25 | 31.9% | 77.7% | ||
| Q2 25 | 32.9% | 77.5% | ||
| Q1 25 | 29.9% | 78.0% | ||
| Q4 24 | 32.9% | 75.5% | ||
| Q3 24 | 32.5% | 75.5% | ||
| Q2 24 | — | 76.8% |
| Q1 26 | 13.8% | — | ||
| Q4 25 | 15.3% | 20.9% | ||
| Q3 25 | 11.6% | 39.0% | ||
| Q2 25 | 16.8% | 31.6% | ||
| Q1 25 | 13.5% | 38.0% | ||
| Q4 24 | 16.7% | 26.7% | ||
| Q3 24 | 14.3% | 24.6% | ||
| Q2 24 | — | 37.3% |
| Q1 26 | 10.1% | 0.9% | ||
| Q4 25 | 11.8% | 18.1% | ||
| Q3 25 | 8.0% | 33.5% | ||
| Q2 25 | 12.4% | 28.0% | ||
| Q1 25 | 10.7% | 32.7% | ||
| Q4 24 | 12.9% | 24.0% | ||
| Q3 24 | 10.3% | 19.0% | ||
| Q2 24 | — | 33.9% |
| Q1 26 | $2.93 | — | ||
| Q4 25 | $3.54 | $1.19 | ||
| Q3 25 | $2.25 | $2.32 | ||
| Q2 25 | $3.49 | $1.76 | ||
| Q1 25 | $2.82 | $2.01 | ||
| Q4 24 | $3.59 | $1.49 | ||
| Q3 24 | $2.67 | $1.24 | ||
| Q2 24 | — | $2.14 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $9.4B | — |
| Total DebtLower is stronger | $5.0B | — |
| Stockholders' EquityBook value | $32.3B | — |
| Total Assets | $67.1B | — |
| Debt / EquityLower = less leverage | 0.16× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $9.4B | — | ||
| Q4 25 | $9.7B | $14.6B | ||
| Q3 25 | $11.5B | $18.2B | ||
| Q2 25 | $9.6B | $8.6B | ||
| Q1 25 | $8.5B | $9.2B | ||
| Q4 24 | $8.3B | $13.7B | ||
| Q3 24 | $5.0B | $14.6B | ||
| Q2 24 | — | $11.4B |
| Q1 26 | $5.0B | — | ||
| Q4 25 | $5.0B | — | ||
| Q3 25 | $5.0B | — | ||
| Q2 25 | $5.0B | — | ||
| Q1 25 | $5.0B | — | ||
| Q4 24 | $5.0B | — | ||
| Q3 24 | $78.6M | — | ||
| Q2 24 | — | — |
| Q1 26 | $31.2B | — | ||
| Q4 25 | $30.9B | $52.6B | ||
| Q3 25 | $31.2B | $51.9B | ||
| Q2 25 | $30.6B | $49.0B | ||
| Q1 25 | $29.2B | $48.3B | ||
| Q4 24 | $29.2B | $46.3B | ||
| Q3 24 | $28.3B | $44.5B | ||
| Q2 24 | — | $43.6B |
| Q1 26 | $67.1B | — | ||
| Q4 25 | $64.7B | $136.9B | ||
| Q3 25 | $65.4B | $129.5B | ||
| Q2 25 | $63.4B | $117.5B | ||
| Q1 25 | $59.9B | $115.1B | ||
| Q4 24 | $59.9B | $117.1B | ||
| Q3 24 | $55.9B | $117.5B | ||
| Q2 24 | — | $112.6B |
| Q1 26 | 0.16× | — | ||
| Q4 25 | 0.16× | — | ||
| Q3 25 | 0.16× | — | ||
| Q2 25 | 0.16× | — | ||
| Q1 25 | 0.17× | — | ||
| Q4 24 | 0.17× | — | ||
| Q3 24 | 0.00× | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | — |
| Free Cash FlowOCF − Capex | $3.7B | — |
| FCF MarginFCF / Revenue | 20.3% | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $12.7B | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $3.8B | — | ||
| Q4 25 | $1.7B | $2.9B | ||
| Q3 25 | $3.9B | $7.8B | ||
| Q2 25 | $3.7B | $3.3B | ||
| Q1 25 | $2.9B | $2.5B | ||
| Q4 24 | $1.0B | $3.5B | ||
| Q3 24 | $3.4B | $9.3B | ||
| Q2 24 | — | $5.6B |
| Q1 26 | $3.7B | — | ||
| Q4 25 | $1.5B | $1.8B | ||
| Q3 25 | $3.8B | $6.8B | ||
| Q2 25 | $3.5B | $2.5B | ||
| Q1 25 | $2.7B | $1.2B | ||
| Q4 24 | $870.3M | $2.5B | ||
| Q3 24 | $3.2B | $8.5B | ||
| Q2 24 | — | $4.8B |
| Q1 26 | 20.3% | — | ||
| Q4 25 | 8.0% | 11.1% | ||
| Q3 25 | 21.6% | 39.6% | ||
| Q2 25 | 19.8% | 16.0% | ||
| Q1 25 | 16.1% | 7.5% | ||
| Q4 24 | 4.9% | 16.1% | ||
| Q3 24 | 19.4% | 51.1% | ||
| Q2 24 | — | 30.1% |
| Q1 26 | 0.8% | — | ||
| Q4 25 | 0.8% | 6.3% | ||
| Q3 25 | 0.6% | 5.7% | ||
| Q2 25 | 1.0% | 4.8% | ||
| Q1 25 | 1.0% | 8.6% | ||
| Q4 24 | 0.9% | 6.0% | ||
| Q3 24 | 1.3% | 4.7% | ||
| Q2 24 | — | 4.9% |
| Q1 26 | 2.09× | — | ||
| Q4 25 | 0.75× | 0.96× | ||
| Q3 25 | 2.77× | 1.35× | ||
| Q2 25 | 1.68× | 0.74× | ||
| Q1 25 | 1.60× | 0.49× | ||
| Q4 24 | 0.45× | 0.92× | ||
| Q3 24 | 2.01× | 2.94× | ||
| Q2 24 | — | 1.03× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ACN
| Products | $5.5B | 30% |
| Health & Public Service | $3.7B | 20% |
| Financial Services | $3.4B | 19% |
| Communications, Media & Technology | $3.1B | 17% |
| Resources | $2.4B | 13% |
MRK
Segment breakdown not available.
